Cargando…
Maintenance of skeletal muscle mass during FOLFIRINOX is a favorable prognostic factor in pancreatic cancer patients
OBJECTIVE: The study aimed to investigate the effect of body composition changes during chemotherapy on clinical outcomes in patients with pancreatic cancer. RESULTS: In patients with locally advanced pancreatic cancer (LAPC), the cross-sectional area of skeletal muscle (SM) and adipose tissue (AT)...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8281692/ https://www.ncbi.nlm.nih.gov/pubmed/34266478 http://dx.doi.org/10.1186/s13104-021-05681-x |
_version_ | 1783722878705860608 |
---|---|
author | Shin, Dong Woo Kim, Minseok Albert Lee, Jong-chan Kim, Jaihwan Hwang, Jin-Hyeok |
author_facet | Shin, Dong Woo Kim, Minseok Albert Lee, Jong-chan Kim, Jaihwan Hwang, Jin-Hyeok |
author_sort | Shin, Dong Woo |
collection | PubMed |
description | OBJECTIVE: The study aimed to investigate the effect of body composition changes during chemotherapy on clinical outcomes in patients with pancreatic cancer. RESULTS: In patients with locally advanced pancreatic cancer (LAPC), the cross-sectional area of skeletal muscle (SM) and adipose tissue (AT) at the level of third lumbar vertebra was measured. The SM and AT ratios indicated the changes during chemotherapy. The patients were classified into three groups based on these ratios: group 1, ≥ 1.00; group 2, 0.85–0.99; group 3, < 0.85. The overall survival (OS) and surgical resection rates were estimated. Fifty-eight patients with LAPC who received first-line FOLFIRINOX were analyzed. Fifteen (25.9%) patients who underwent resection showed maintained BMI, SM, and AT as compared to the patients who did not undergo resection. As the SM ratio decreased, the risk for death increased significantly. Further, the resection rate was significantly higher in patients with maintained SM compared to those with low SM ratio. On the contrary, the change in AT ratio was not associated with OS and resection rate; however, significant decrease in AT more than 15% showed poor clinical outcomes. Maintenance of SM during chemotherapy is a reliable prognostic factor indicating longer OS and higher resection rate. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13104-021-05681-x. |
format | Online Article Text |
id | pubmed-8281692 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-82816922021-07-16 Maintenance of skeletal muscle mass during FOLFIRINOX is a favorable prognostic factor in pancreatic cancer patients Shin, Dong Woo Kim, Minseok Albert Lee, Jong-chan Kim, Jaihwan Hwang, Jin-Hyeok BMC Res Notes Research Note OBJECTIVE: The study aimed to investigate the effect of body composition changes during chemotherapy on clinical outcomes in patients with pancreatic cancer. RESULTS: In patients with locally advanced pancreatic cancer (LAPC), the cross-sectional area of skeletal muscle (SM) and adipose tissue (AT) at the level of third lumbar vertebra was measured. The SM and AT ratios indicated the changes during chemotherapy. The patients were classified into three groups based on these ratios: group 1, ≥ 1.00; group 2, 0.85–0.99; group 3, < 0.85. The overall survival (OS) and surgical resection rates were estimated. Fifty-eight patients with LAPC who received first-line FOLFIRINOX were analyzed. Fifteen (25.9%) patients who underwent resection showed maintained BMI, SM, and AT as compared to the patients who did not undergo resection. As the SM ratio decreased, the risk for death increased significantly. Further, the resection rate was significantly higher in patients with maintained SM compared to those with low SM ratio. On the contrary, the change in AT ratio was not associated with OS and resection rate; however, significant decrease in AT more than 15% showed poor clinical outcomes. Maintenance of SM during chemotherapy is a reliable prognostic factor indicating longer OS and higher resection rate. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13104-021-05681-x. BioMed Central 2021-07-15 /pmc/articles/PMC8281692/ /pubmed/34266478 http://dx.doi.org/10.1186/s13104-021-05681-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Note Shin, Dong Woo Kim, Minseok Albert Lee, Jong-chan Kim, Jaihwan Hwang, Jin-Hyeok Maintenance of skeletal muscle mass during FOLFIRINOX is a favorable prognostic factor in pancreatic cancer patients |
title | Maintenance of skeletal muscle mass during FOLFIRINOX is a favorable prognostic factor in pancreatic cancer patients |
title_full | Maintenance of skeletal muscle mass during FOLFIRINOX is a favorable prognostic factor in pancreatic cancer patients |
title_fullStr | Maintenance of skeletal muscle mass during FOLFIRINOX is a favorable prognostic factor in pancreatic cancer patients |
title_full_unstemmed | Maintenance of skeletal muscle mass during FOLFIRINOX is a favorable prognostic factor in pancreatic cancer patients |
title_short | Maintenance of skeletal muscle mass during FOLFIRINOX is a favorable prognostic factor in pancreatic cancer patients |
title_sort | maintenance of skeletal muscle mass during folfirinox is a favorable prognostic factor in pancreatic cancer patients |
topic | Research Note |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8281692/ https://www.ncbi.nlm.nih.gov/pubmed/34266478 http://dx.doi.org/10.1186/s13104-021-05681-x |
work_keys_str_mv | AT shindongwoo maintenanceofskeletalmusclemassduringfolfirinoxisafavorableprognosticfactorinpancreaticcancerpatients AT kimminseokalbert maintenanceofskeletalmusclemassduringfolfirinoxisafavorableprognosticfactorinpancreaticcancerpatients AT leejongchan maintenanceofskeletalmusclemassduringfolfirinoxisafavorableprognosticfactorinpancreaticcancerpatients AT kimjaihwan maintenanceofskeletalmusclemassduringfolfirinoxisafavorableprognosticfactorinpancreaticcancerpatients AT hwangjinhyeok maintenanceofskeletalmusclemassduringfolfirinoxisafavorableprognosticfactorinpancreaticcancerpatients |